Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1102 of 5804
-
Experimental drug cocktail takes on Hard-to-Treat cancers
Disease control Recruiting nowThis study was designed to evaluate the efficacy and safety of 7MW3711 in combination with JS207 in subjects with solid tumor.
Phase: PHASE1, PHASE2 • Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Vegan diet may tame autoimmune hepatitis in kids
Disease control Recruiting nowPediatric autoimmune liver diseases (AILDs), including autoimmune hepatitis (AIH) and overlap syndromes like sclerosing cholangitis, are among the most common chronic liver conditions in the pediatric population. Currently, the treatment for AIH often involves long-term use of im…
Phase: NA • Sponsor: Institute of Liver and Biliary Sciences, India • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Neck zap may ease Parkinson's leg stiffness
Symptom relief Recruiting nowThis study is designed to better understand the mechanisms contributing to impaired activation of leg muscles in people with Parkinson's disease (PD) and to test if stimulation of a nerve at the neck can improve muscle activation, walking and balance.
Phase: NA • Sponsor: University of Minnesota • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
New hope for advanced kidney cancer: experimental drug enters human trials
Disease control Recruiting nowThis study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look a…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New PET scan could spot hidden aggressive prostate cancer in men avoiding treatment
Diagnosis Recruiting nowThis investigator-initiated, prospective study evaluates the diagnostic utility of rhPSMA-7.3 (¹⁸F) PET/CT (flotufolastat F18, marketed as POSLUMA®) in men with biopsy-proven, low-risk or favorable intermediate-risk prostate cancer managed with active surveillance. The study aims…
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Diagnosis
Last updated Jun 27, 2026 09:08 UTC
-
Can a sleep pill help smokers kick the habit?
Symptom relief Not yet recruitingTobacco use is the leading cause of preventable death in the U.S., with 480,000 deaths per year and 7.7 million deaths globally. A major clinical symptom associated with abstinence from both licit and illicit drugs is insomnia, which is a clinically verified, major risk factor fo…
Phase: PHASE4 • Sponsor: Legacy Health System • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
New hope for Hard-to-Treat prostate cancer? early trial launches
Disease control Recruiting nowThis first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New pill shows promise for tough lung cancers
Disease control Not yet recruitingThis is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients with advanced or metastatic non-small cell lung canc…
Phase: PHASE1, PHASE2 • Sponsor: Nerviano Medical Sciences (Shanghai) Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug SLN12140 aims to control PNH in early trial
Disease control Not yet recruitingThe goal of this clinical trial is to learn if drug SLN12140 works to treat Complement Inhibitor-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria in adults. It will also learn about the safety, pharmacokinetic characteristics, and dosing of drug SLN12140. The study is div…
Phase: PHASE2 • Sponsor: Linno Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Laser zaps eye drops: new study tests glaucoma treatment
Disease control Recruiting nowThis is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma. The st…
Sponsor: The Eye Institute of West Florida • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Experimental drug aims to shield kidneys in sepsis patients
Disease control Recruiting nowThis study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within 72 hours of the onset of sepsis. Eligible participa…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could these eye drops replace cataract surgery?
Disease control Recruiting nowThis is a multicenter, randomized, double-masked, placebo-controlled pilot study conducted in the United States (US) in subjects with age-related cataract in one or both eyes. Approximately 40 subjects with age-related cataract will be stratified by race and Best Corrected Dista…
Phase: PHASE2 • Sponsor: Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug aims to improve schizophrenia treatment and reduce relapse
Disease control Recruiting nowThe purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could VR and a brain zapper lift Post-Stroke depression?
Symptom relief Not yet recruitingThis study investigates whether combining virtual reality mindfulness-based cognitive therapy (VR-MBCT) with transcranial direct current stimulation (tDCS) can effectively treat depression occurring after a stroke (post-stroke depression, PSD). The goal is to determine if this co…
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
New spray could stop radiation burns in cancer patients
Prevention TerminatedRadiotherapy always results in many complications such as radiation dermatitis,dry mouth, cranial nerve damage, and swallowing function. Among them,radiation dermatitis is confirmed to occur in the majority of tumor patientsreceiving radiotherapy, which not only affects the appea…
Phase: NA • Sponsor: West China Hospital • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Heart patients face dilemma: aspirin or not before colonoscopy?
Disease control Recruiting nowOne in 4 adults between 50 and 80 reports taking regular aspirin. The prevalence of aspirin uses increases with age as well as co-morbid vascular diseases. Patients with cardiovascular diseases are at risk of developing colorectal neoplasms. In patients undergoing screening colon…
Phase: PHASE3 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New Chemo-Oil combo shows promise for liver cancer patients who Can't have surgery
Disease control OngoingBackground: In the treatment of liver cancer, TACE (transarterial chemoembolization) combined with ablation is commonly used. The chemotherapeutic drug iodized oil emulsion prepared by the ultra-stable homogeneous mixture formulation technology (SHIFT) is stable, efficient, and h…
Phase: NA • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
100,000-Person study pits Weight-Loss drugs against heart attacks
Disease control CompletedInvestigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how…
Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for breast cancer brain metastases: drug combo plus radiation shows promise
Disease control Recruiting nowAngiogenesis inhibition represents a significant therapeutic target in breast cancer; however, despite its theoretical feasibility, progress in advanced breast cancer has been slow. Currently, there is a lack of prospective data supporting the selection of tyrosine kinase inhibit…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Could a simple asthma drug prevent a dangerous immunotherapy side effect?
Disease control Recruiting nowThe introduction of immune checkpoint inhibitors (immunotherapy) that stimulate our immune system to recognize and attack cancer cells has been one of the most exciting advances in oncology over the last decade. These medications are now employed across almost half of cancer type…
Phase: PHASE2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC